IsoPlexis Using Recent Influx of Funds for Automated Single-Cell Analysis Platform – GenomeWeb
|
IsoPlexis Using Recent Influx of Funds for Automated Single-Cell Analysis Platform
GenomeWeb NEW YORK (GenomeWeb) – Omics firm IsoPlexis is developing an automated version of its single-cell analysis platform for use in large clinical trials of CAR–T therapies for blood cancers. The Branford, Connecticut-based company is using a $1.8 million … |
